These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22430608)

  • 1. Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(4):2372-8. PubMed ID: 22430608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
    Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
    Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma.
    Ogura M; Morishima Y; Kagami Y; Watanabe T; Itoh K; Igarashi T; Hotta T; Kinoshita T; Ohashi Y; Mori S; Terauchi T; Tobinai K
    Cancer Sci; 2006 Apr; 97(4):305-12. PubMed ID: 16630123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
    Tsurumi H; Hara T; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Shimizu M; Takahashi T; Takami T; Moriwaki H
    Leuk Lymphoma; 2012 Feb; 53(2):247-53. PubMed ID: 21827339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
    Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
    Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
    Ferrario A; Pulsoni A; Olivero B; Rossi G; Vitolo U; Tedeschi A; Merli F; Rigacci L; Stelitano C; Goldaniga M; Mannina D; Musto P; Rossi F; Gamba E; Baldini L
    Cancer; 2012 Aug; 118(16):3954-61. PubMed ID: 22179904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas.
    Yun H; Zhang HL; Wang HQ
    Med Oncol; 2015 Jan; 32(1):353. PubMed ID: 25511319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.
    Ohnishi K; Ohmachi K; Ando K; Yamamoto K; Ito T; Tanimoto M; Ohbayashi K; Ohyashiki K; Tsukasaki K; Naito K; Suzuki T; Ono T; Miyamura K; Kagami Y; Kinoshita T; Hotta T; Ogura M
    J Clin Exp Hematop; 2021 Sep; 61(3):162-167. PubMed ID: 34193755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
    Lin TS; Blum KA; Fischer DB; Mitchell SM; Ruppert AS; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Johnson AJ; Schaaf LJ; Grever MR; Byrd JC
    J Clin Oncol; 2010 Jan; 28(3):418-23. PubMed ID: 20008633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
    Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
    Hou Y; Wang HQ; Fu K; Liu XM; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):306-10. PubMed ID: 22781046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
    Kikukawa M; Miyazaki K; Kiuchi A; Abe S; Fujii H; Kanaya K; Shin K; Iwamoto T
    Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.